AstraZeneca Pharmaceuticals LP

Baselga resigned from Memorial Sloan Kettering following reports he failed to disclose his financial ties to various pharma companies in articles he published.

The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.

An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.

AstraZeneca released data from two clinical trials of roxadustat in anemia and of its trial of Lynparza in ovarian cancer. All the trials had positive results.

Merck & Co. found itself with two new approvals this week. The FDA approved Lynparza (codeveloped by AstraZeneca and Merck) and also approved Merck’s Keytruda. Both of these drugs were approved for new indications.

Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.

AstraZeneca and its MedImmune division announced results from its Phase III EAGLE clinical trial. Imfinzi, in combination with tremelimumab, an anti-CTLA4 antibody, compared to standard-of-care (SoC) chemotherapy, failed to meet its primary endpoints in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed after platinum-based chemotherapy, regardless of the PD-L1 status of their cancer.

The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

As Britain continues to move forward with its plans to leave the European Union, a new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.